Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis
2013
Lin, Ko-Ming | Lin, Jing-Chi | Tseng, Wen-Yi | Cheng, Tien-Tsai
The B-cell depletion agent rituximab (RTX) is used in lymphoma and rheumatoid arthritis (RA), and there have been several case reports of an RTX-induced reactivation of hepatitis C virus in patients with lymphoma. However, there have been no papers detailing hepatitis C virus reactivation after RTX therapy in a patient with RA. Here we report a case of RTX-induced hepatitis C virus reactivation in a patient with RA. Physicians should be aware that a close follow-up of liver function and viral load is mandatory after RTX therapy in patients with RA and concomitant hepatitis C.
显示更多 [+] 显示较少 [-]